New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 16, 2012
10:28 EDTAAWW, SEM, DELL, CQB, NVDA, FMS, DGIT, CMCSA, WSO, ACOM, MAS, NRP, PHM, RLOC, DE, INCY, AMZNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Amazon.com (AMZN) downgraded to Equal Weight from Overweight at Morgan Stanley...Incyte (INCY) downgraded to Equal Weight from Overweight at Morgan Stanley...Deere (DE) downgraded to Market Perform from Outperform at Wells Fargo...Natural Resource (NRP) downgraded to Market Perform from Outperform at Wells Fargo...Digital Generation (DGIT) downgraded to Perform from Outperform at Oppenheimer...Digital Generation downgraded to Neutral from Buy at Janney Capital...Select Medical (SEM) downgraded to Market Perform from Outperform at JMP Securities...Masco (MAS) downgraded to Neutral from Buy at Citigroup...Fresenius Medical (FMS) downgraded to Neutral from Buy at Citigroup...Atlas Air (AAWW) downgraded to Hold from Buy at Dahlman Rose...Ancestry.com (ACOM) downgraded to Neutral from Buy at BofA/Merrill...NVIDIA (NVDA) downgraded to Neutral from Buy at BofA/Merrill...ReachLocal (RLOC) downgraded to Underperform from Neutral at BofA/Merrill...Watsco (WSO) downgraded to Neutral from Buy at SunTrust...Chiquita Brands (CQB) downgraded to Hold from Buy at BB&T...Pulte Group (PHM) downgraded to Neutral from Buy at UBS...Comcast (CMCSA) downgraded to Hold from Buy at Argus...Dell (DELL) downgraded to Outperform from Buy at CLSA.
News For AMZN;INCY;DE;NRP;DGIT;SEM;MAS;FMS;AAWW;ACOM;NVDA;RLOC;WSO;CQB;PHM;CMCSA;DELL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 10, 2014
07:26 EDTPHMPulteGroup price target raised to $26 from $23 at Susquehanna
Susquehanna raised its price target on PulteGroup to reflect the company's current return profile, which has done better than its historic average. Susquehanna reiterated its Positive rating on PulteGroup shares.
06:34 EDTAMZNAmazon's publishing boss to leave company, Seattle Times reports
The boss of Amazon's publishing division is leaving after a little more than a year in the job, The Seattle Times reports, citing a confirmed statement from an Amazon spokeswoman. Daphne Durham was at the company for over 15 years. Mikyla Bruder will assume most of Durhamís responsibilities. Reference Link
06:18 EDTAMZNAmazon's Twitch to acquire GoodGame agency, terms not disclosed
Subscribe for More Information
December 9, 2014
15:45 EDTCQBGabelli raises stake in Chiquita to 8.16% from 6.52%
Subscribe for More Information
15:03 EDTCMCSADiscovery Communications rises after CEO sees outperforming U.S. peers
Subscribe for More Information
11:11 EDTCMCSADiscovery, Hulu announce new distribution agreement
Subscribe for More Information
07:55 EDTAMZNAmazon.com continuing to gain share, says Pacific Crest
After conducting a consumer technology survey, Pacific Crest reports that 81% of respondents plan to shop at Amazon this holiday, while 31% plan to do most or nearly all of their online holiday shopping on the website. The firm thinks the company is continuing to gain share and it recommends buying the stock.
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
06:48 EDTCMCSAAnalysts say Netflix undermining TV ad revenue, NY Times reports
Subscribe for More Information
06:29 EDTAMZNAmazon warns of moving more drone research abroad, WSJ reports
Subscribe for More Information
06:25 EDTCMCSAComcast, USA Network trialing 'Playing House' on-demand , WSJ reports
Comcast (CMCSA) is planning to make new episodes of the sitcom "Playing House" available first on its on-demand service and air them on the USA Network the following week, The Wall Street Journal reports. Reference Link
06:23 EDTAMZNAmazon.com testing faster deliveries through bikes, drones, WSJ reports
Subscribe for More Information
06:16 EDTAMZNAmazon unveils 'Make an Offer' for customers to negotiate lower prices
Amazon.com has announced the "Make an Offer" experience that allows customers to negotiate even lower prices on thousands of items. Expanding on Amazonís traditional fixed price model, the new pricing feature allows customers to offer to buy items at even lower prices. If agreed upon, customers can then purchase the items at a savings from the listed price. To start, more than 150,000 items from sellers on Amazon are enabled with the "Make an Offer" experience across Sports and Entertainment Collectibles, Collectible Coins and Fine Art. The new feature will expand to hundreds of thousands of items from sellers in 2015. The "Make an Offer" feature is not an auction format. All negotiations are 1:1 and private between individual customers and sellers. A seller is able to accept a customerís offer at any time. The intention is to lower prices, and a customer negotiating with a seller will never pay more than the listed price.
05:34 EDTAMZNChannelAdvisor says Amazon November SSS up 35.7%, eBay up 9.8%
Subscribe for More Information
December 8, 2014
16:00 EDTAMZNOptions Update; December 8, 2014
Subscribe for More Information
14:36 EDTCMCSATime Warner Cable CEO reports strong trends in October, November, says UBS
Subscribe for More Information
14:30 EDTPHMPulteGroup December volatility elevated into investor day
Subscribe for More Information
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
08:50 EDTAMZNAmazon increasing robot fulfilment use faster than expected, says Janney Capital
Subscribe for More Information
06:30 EDTAMZNAmazon's German workers strike again, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use